591 related articles for article (PubMed ID: 28255011)
1. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
Ferrantini C; Coppini R; Pioner JM; Gentile F; Tosi B; Mazzoni L; Scellini B; Piroddi N; Laurino A; Santini L; Spinelli V; Sacconi L; De Tombe P; Moore R; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Tesi C; Poggesi C
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28735292
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.
Flenner F; Friedrich FW; Ungeheuer N; Christ T; Geertz B; Reischmann S; Wagner S; Stathopoulou K; Söhren KD; Weinberger F; Schwedhelm E; Cuello F; Maier LS; Eschenhagen T; Carrier L
Cardiovasc Res; 2016 Jan; 109(1):90-102. PubMed ID: 26531128
[TBL] [Abstract][Full Text] [Related]
4. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
5. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.
Coppini R; Ferrantini C; Yao L; Fan P; Del Lungo M; Stillitano F; Sartiani L; Tosi B; Suffredini S; Tesi C; Yacoub M; Olivotto I; Belardinelli L; Poggesi C; Cerbai E; Mugelli A
Circulation; 2013 Feb; 127(5):575-84. PubMed ID: 23271797
[TBL] [Abstract][Full Text] [Related]
6. Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy.
Crocini C; Ferrantini C; Scardigli M; Coppini R; Mazzoni L; Lazzeri E; Pioner JM; Scellini B; Guo A; Song LS; Yan P; Loew LM; Tardiff J; Tesi C; Vanzi F; Cerbai E; Pavone FS; Sacconi L; Poggesi C
J Mol Cell Cardiol; 2016 Feb; 91():42-51. PubMed ID: 26714042
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy.
Coppini R; Santini L; Olivotto I; Ackerman MJ; Cerbai E
Cardiovasc Res; 2020 Jul; 116(9):1585-1599. PubMed ID: 32365196
[TBL] [Abstract][Full Text] [Related]
8. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.
Ferrantini C; Pioner JM; Mazzoni L; Gentile F; Tosi B; Rossi A; Belardinelli L; Tesi C; Palandri C; Matucci R; Cerbai E; Olivotto I; Poggesi C; Mugelli A; Coppini R
Br J Pharmacol; 2018 Jul; 175(13):2635-2652. PubMed ID: 29579779
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Analysis of Troponin C Knock-In (A8V) Mice: Evidence that TNNC1 Is a Hypertrophic Cardiomyopathy Susceptibility Gene.
Martins AS; Parvatiyar MS; Feng HZ; Bos JM; Gonzalez-Martinez D; Vukmirovic M; Turna RS; Sanchez-Gonzalez MA; Badger CD; Zorio DAR; Singh RK; Wang Y; Jin JP; Ackerman MJ; Pinto JR
Circ Cardiovasc Genet; 2015 Oct; 8(5):653-664. PubMed ID: 26304555
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Undrovinas AI; Belardinelli L; Undrovinas NA; Sabbah HN
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1(Suppl 1):S169-S177. PubMed ID: 16686675
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of late Na+ current, a novel target to improve diastolic function and electrical abnormalities in Dahl salt-sensitive rats.
Chi L; Belardinelli L; Zeng A; Hirakawa R; Rajamani S; Ling H; Dhalla AK
Am J Physiol Heart Circ Physiol; 2016 May; 310(10):H1313-20. PubMed ID: 26993228
[TBL] [Abstract][Full Text] [Related]
12. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.
Cappetta D; Esposito G; Coppini R; Piegari E; Russo R; Ciuffreda LP; Rivellino A; Santini L; Rafaniello C; Scavone C; Rossi F; Berrino L; Urbanek K; De Angelis A
Br J Pharmacol; 2017 Nov; 174(21):3696-3712. PubMed ID: 28320043
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat.
Aistrup GL; Gupta DK; Kelly JE; O'Toole MJ; Nahhas A; Chirayil N; Misener S; Beussink L; Singh N; Ng J; Reddy M; Mongkolrattanothai T; El-Bizri N; Rajamani S; Shryock JC; Belardinelli L; Shah SJ; Wasserstrom JA
Am J Physiol Heart Circ Physiol; 2013 Oct; 305(7):H1068-79. PubMed ID: 23873796
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy.
Ryba DM; Warren CM; Karam CN; Davis RT; Chowdhury SAK; Alvarez MG; McCann M; Liew CW; Wieczorek DF; Varga P; Solaro RJ; Wolska BM
Circ Heart Fail; 2019 Nov; 12(11):e005835. PubMed ID: 31684756
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
[TBL] [Abstract][Full Text] [Related]
17. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
18. Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy.
Huang Y; Lu H; Ren X; Li F; Bu W; Liu W; Dailey WP; Saeki H; Gabrielson K; Abraham R; Eckenhoff R; Gao WD
Cardiovasc Res; 2020 May; 116(6):1175-1185. PubMed ID: 31424496
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na
Nie J; Duan Q; He M; Li X; Wang B; Zhou C; Wu L; Wen Z; Chen C; Wang DW; Alsina KM; Wehrens XHT; Wang DW; Ni L
J Cell Physiol; 2019 Jul; 234(7):11587-11601. PubMed ID: 30488495
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
